Market Size of Retinal Biologics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Retinal Biologics Market Analysis
The retinal biologics market studied is anticipated to record a CAGR of nearly 6.8% during the forecast period.
COVID-19 pandemic has had a substantial impact on the retinal biologics market initially. The global lockdown has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. As per the study "Retinal findings in patients with COVID-19: Results from the SERPICO-19 study," published in September 2020, COVID-19 could affect the retina. Retinal veins diameter seems directly correlated with the disease severity. Thus, during COVID-19, retinal diseases increased, impacting the demand for retinal biologics. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the market is expected to gain traction due to the significant increase in the need for retinal globally.
Further, the rising burden of retinal diseases, the increasing diabetic patient population, increasing R&D activities, and the growing number of FDA approvals are among the major factors driving the growth of the studied market. Currently, there has been a tremendous increase in the diabetic population, across the globe, over the past decade. Several reports and surveys documented a drastic increase in the diabetic population based on the changing lifestyle and habits. For instance, according to the Asian Diabetics Prevention Initiatives, the higher contribution of diabetes burden are in China and India, and by 2030, both China and India combined may have almost half a billion diabetic patients.
As per the study "Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis," published in November 2021, the number of adults globally with diabetic retinopathy was estimated to be 103.12 million in 2020, and by 2045, the numbers are projected to increase to 160.50 million. Thus, the growing burden of retinal diseases such as diabetic retinopathy may increase the demand for biologic treatment, which is expected to further drive the market growth.
Furthermore, in February 2022, Eyebiotech Limited secured USD 65 million in a series A financing round for developing a diverse pipeline of therapies for eye diseases such as wet age-related macular degeneration, diabetic retinopathy, etc. Therefore, rising investments may also boost innovation in the studied market, thereby driving the studied market growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, stringent regulatory process and initial high capital investment is likely to impede the market growth.
Retinal Biologics Industry Segmentation
As per the report's scope, biologics are generally produced from living organisms such as microorganisms or animal or plant cells. Retinal biologics refer to bioengineered molecules implanted inside the eyes to heal chronic retinal diseases. The Retinal Biologics Market is Segmented by Drug Class (VEGF-A Antagonist, TNF-a Inhibitor), Disease Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.
| By Drug Class | |
| VEGF-A Antagonist | |
| TNF-a Inhibitor |
| By Disease Indication | |
| Macular Degeneration | |
| Diabetic Retinopathy | |
| Uveitis | |
| Other Disease Indications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Retinal Biologics Market Size Summary
The retinal biologics market is poised for significant growth, driven by an increasing prevalence of retinal diseases and a rising diabetic population globally. The market's expansion is supported by heightened research and development activities, along with a growing number of FDA approvals for new treatments. The COVID-19 pandemic initially disrupted the market by affecting supply chains and increasing the incidence of retinal conditions, which subsequently boosted the demand for retinal biologics. The market is characterized by the development of innovative therapies and substantial investments, such as Eyebiotech Limited's financing for eye disease treatments, which are expected to further propel market growth. However, challenges such as stringent regulatory processes and high initial capital investments may hinder progress.
In North America, particularly the United States, the retinal biologics market is expected to experience robust growth due to the high burden of diabetic retinopathy and other retinal disorders. Strategic initiatives by key players, including product launches and regulatory approvals, are contributing to market expansion. Companies like F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and AbbVie Inc. hold significant market shares and are actively involved in mergers and acquisitions to strengthen their positions. The competitive landscape is marked by ongoing clinical studies and the introduction of new therapies, which are anticipated to drive the market forward. Overall, the retinal biologics market is set to grow, supported by technological advancements and increasing demand for effective treatments.
Retinal Biologics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Burden of Retinal Diseases and Increasing Diabetic Patient Population
-
1.2.2 Increasing R&D Activities and Growing Number of FDA Approvals
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Process and Initial High Capital Investment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - UDS Million)
-
2.1 By Drug Class
-
2.1.1 VEGF-A Antagonist
-
2.1.2 TNF-a Inhibitor
-
-
2.2 By Disease Indication
-
2.2.1 Macular Degeneration
-
2.2.2 Diabetic Retinopathy
-
2.2.3 Uveitis
-
2.2.4 Other Disease Indications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Retinal Biologics Market Size FAQs
What is the current Global Retinal Biologics Market size?
The Global Retinal Biologics Market is projected to register a CAGR of 6.80% during the forecast period (2024-2029)
Who are the key players in Global Retinal Biologics Market?
F. Hoffmann-La Roche Ltd , Regeneron Pharmaceuticals Inc. , AbbVie Inc. , MeiraGTx Limited and Oxurion NV are the major companies operating in the Global Retinal Biologics Market.
